Navigation Links
Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
Date:2/11/2009

se II bavituximab lung cancer trial. We will continue assessing patients for anti-tumor activity as treatment and follow-up progress, and we look forward to sharing more data from these trials in the coming months."

The primary objective of this multi-center Phase II trial is to assess overall tumor response rate. Secondary objectives include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. All tumor responses in the trial are being evaluated using RECIST criteria. Patients may continue to receive bavituximab alone after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable. The trial is being conducted in India according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) guidelines.

The World Health Organization reports that breast cancer is the most commonly diagnosed cancer in women and is second only to lung cancer as a leading cause of female cancer deaths. The National Cancer Institute estimates that approximately 182,460 U.S. women were diagnosed with breast cancer in 2008 and 40,480 women died of the disease in the U.S. alone.

Bavituximab is a monoclonal antibody that binds to the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. By binding to PS, bavituximab is believed to help mobilize the body's immune system to destroy the tumor and the tumor blood vessels. Bavituximab currently is in two separate Phase II combination therapy trials for the treatment of advanced breast cancer and a Phase II combination therapy trial for the treatment of non-small cell lung cancer. A Phase I bavituximab monotherapy trial in advanced solid cancers is also continuing.

About P
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... Orthopedic surgeons at Lourdes Medical Center of ... Rotator Cuff System, a new implant to treat a common source of shoulder pain ... regeneration of additional tendon tissue, which could allow for faster healing and a decreased ...
(Date:7/29/2015)... ... July 29, 2015 , ... Wedding season is in full swing, which means bridal beauty prep ... looking good on the big day. Every bride wants to look and feel beautiful, but ... , According to a recent study by the American Academy of Facial ...
(Date:7/29/2015)... ... July 29, 2015 , ... Fastline ... fall of 2015 on RFD-TV. , Fastline is dedicated to quality agricultural advertising, ... which contains the largest and freshest searchable agriculture equipment database in the world. ...
(Date:7/29/2015)... ... 2015 , ... A June 10, 2015 article from the News-Press, entitled " ... of having regular skin cancer screenings from an early age. Skin cancer can strike ... caught early, skin cancer is rarely fatal; however, if left alone for too long, ...
(Date:7/29/2015)... Madison, Wis. (PRWEB) , ... July 29, 2015 ... ... enrolled its first two patients in a Clinical Performance Study for the Invisiport ... includes 4.4 and 6 French catheter options, offers a less invasive, patient-friendly alternative ...
Breaking Medicine News(10 mins):Health News:Lourdes Orthopedics First in NJ to Offer Bioinductive Implant for Rotator Cuff Repair 2Health News:Lourdes Orthopedics First in NJ to Offer Bioinductive Implant for Rotator Cuff Repair 3Health News:Say I Do To Surgery: Bridal Beauty On The Rise According to New Survey 2Health News:Say I Do To Surgery: Bridal Beauty On The Rise According to New Survey 3Health News:Fastline Publications to Partner with American Farmer in Upcoming Episode Airing on RFD-TV 2Health News:Get Checked for Skin Cancer Early and Often 2Health News:Get Checked for Skin Cancer Early and Often 3Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 2Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 3
... Goodwin HealthDay Reporter , THURSDAY, Sept. 8 (HealthDay ... the death of a child in infancy have an increased ... suggests. Researchers from the United Kingdom looked at census ... child between 1971 and 2006 or whose child died before ...
... at the University of Toronto have developed a therapy ... catheters, artificial joints and other "in-dwelling" medical devices. Their ... Pathogens on September 8th. The therapy targets ... devices because they are composed of biofilmscomplex groupings of ...
... September 7, 2011 (BRONX, NY) In 2004, the ... in Africa. As a result, millions of Africans are now ... been available in the developed world. While research shows that ... about the actual deployment and circumstances of treatment. ...
... HealthDay Reporter , THURSDAY, Sept. 8 (HealthDay News) -- ... rise, reaching 22.6 million, or 8.9 percent of the population, ... has largely been driven by more marijuana use, according to ... fact, in 2010 some 17.4 million Americans were using marijuana, ...
... given before or after breast-conserving therapy (BCT) does not ... success is due more to biologic factors than chemotherapy ... University of Texas MD Anderson Cancer Center. Presented ... also found that neoadjuvant chemotherapy (given before surgery), often ...
... HealthDay Reporter , THURSDAY, Sept. 8 (HealthDay News) ... when the hijacked planes with their terrified passengers ripped into ... are incomplete, they,re burned into her memory just the same. ... mother glued to the TV, watching the Twin Towers collapse. ...
Cached Medicine News:Health News:Losing Child in First Year Might Raise Early Death Risk for Parent 2Health News:Losing Child in First Year Might Raise Early Death Risk for Parent 3Health News:Combination therapy rids common infection from implanted medical devices 2Health News:Einstein to utilize electronic medical records system to analyze HIV/AIDS in central Africa 2Health News:More U.S. Adults Using Illegal Drugs: Report 2Health News:More U.S. Adults Using Illegal Drugs: Report 3Health News:Chemotherapy is as effective before breast cancer surgery as after 2Health News:9/11 a Life-Defining Day for the Young 2Health News:9/11 a Life-Defining Day for the Young 3Health News:9/11 a Life-Defining Day for the Young 4
(Date:7/29/2015)... SAN DIEGO , July 29, 2015  ViaCyte, Inc., a ... therapy for the treatment of diabetes in clinical trials, today announced ... called STEP ONE, or S afety, T olerability, and ... One Diabetes.  The new site, which is the first ... of Alberta Hospitals in Edmonton , Alberta.  ...
(Date:7/29/2015)... July 27, 2015 Research ... the "Pharmaceutical Packaging Market by Packaging Type, by ... Europe, Asia-Pacific, RoW) - Forecasts to 2020" report ... market demand, by value is estimated to reach above ... market is anticipated to show a steady growth rate ...
(Date:7/29/2015)... , July 29, 2015 KaloBios Pharmaceuticals, ... focused on developing innovative therapies to benefit patients with ... oncology, announced today that it received a formal determination ... the company that it is now compliant with the ... NASDAQ Global Market and is no longer subject to ...
Breaking Medicine Technology:ViaCyte Announces Second Clinical Trial Site at University of Alberta 2ViaCyte Announces Second Clinical Trial Site at University of Alberta 3ViaCyte Announces Second Clinical Trial Site at University of Alberta 4Pharmaceutical Packaging Market by Packaging Type, Raw Material & Drug Delivery Type - Forecasts to 2020 for the $80 Billion Industry 2Pharmaceutical Packaging Market by Packaging Type, Raw Material & Drug Delivery Type - Forecasts to 2020 for the $80 Billion Industry 3KaloBios Regains Compliance with NASDAQ Minimum Bid Price Requirement 2KaloBios Regains Compliance with NASDAQ Minimum Bid Price Requirement 3KaloBios Regains Compliance with NASDAQ Minimum Bid Price Requirement 4
... CYBX ) today announced that Dan Moore, President and ... present at the 22nd Annual Piper Jaffray Health Care Conference ... PM ET.  The conference session and webcast will be audio ... will host a webcast of the presentation live and by ...
... Patients with Chronic Obstructive Pulmonary Disease, or COPD, ... burden they must deal with and as a loss ... by GlaxoSmithKline.  Patients participating in the research characterized their ... loss of energy, loss of control, loss of independence ...
Cached Medicine Technology:Cyberonics to Present at 22nd Annual Piper Jaffray Health Care Conference 2COPD Patients Reveal Disease Progression Leads to Physical and Social Isolation and Increased Reliance on the Internet(1) 2COPD Patients Reveal Disease Progression Leads to Physical and Social Isolation and Increased Reliance on the Internet(1) 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: